Sotera Health Company's stock plummeted 5.03% during intraday trading on Tuesday, following the release of its fourth-quarter 2025 financial results and 2026 outlook.
The company reported a Q4 pretax profit of $70.5 million, which fell short of the IBES estimate of $96.4 million. This miss appears to be a primary driver behind the stock's decline. For the full year 2026, Sotera Health provided adjusted EPS guidance in the range of $0.93 to $1.01, which aligns closely with the FactSet consensus estimate of $0.94.
While the company delivered a revenue beat for Q4 and showed year-over-year growth, the significant shortfall in pretax profit compared to analyst expectations likely prompted a negative market reaction during the session.
Comments